Header Image
News Room / The Million-Dollar Volkswagen and 10b5-1 Plans

The Million-Dollar Volkswagen and 10b5-1 Plans

Dr. Jeff Stein, former President and CEO of Trius Therapeutics and former Chairman of the Antibiotics Working Group (AWG), today published a new blog post as a Key Opinion Leader on The Chairman's Blog. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.

Discussing the 10b5-1 trading plan, Dr. Stein points out the effect of these plans on newly public biotech companies, especially those with thinly traded stock. He gives advice based on his experiences at Trius Therapeutics for newly public companies setting up these trading plans, "Until the company matures, think of your stock position more like a real estate holding rather than a checking account with an ATM card." Read the full blog post from Dr. Stein on TheChairmansBlog.com (http://www.thechairmansblog.com/key-opinion-leaders/jeff-stein/million-dollar-volkswagen-10b5-1-plans/).

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publically and privatively held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. In addition to management`s insightful blog posts, TheChairmansBlog.com staff and aggregate partners contribute articles on finance, technology, health, and energy while providing updated market trends, news, and information. http://www.thechairmansblog.com/